Why is this study being conducted?
Alzheimer’s disease is the leading cause of cognitive impairment and dementia worldwide. The purpose of this study is to evaluate a potential new treatment for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease.
Who is eligible to participate in this study?
You may be able to take part in this trial if you:
- Are between 50 and 80 years of age
- Have early Alzheimer's disease
- Weigh between 40 kg and 120 kg, with a BMI between 17 and 35 kg/m2
Additional eligibility criteria may apply and will be discussed directly with the Clinical Trial Coordinator.
What happens during the study?
Trial duration will be about 2 years and you will have about 25 trial visits.
Trial site visits will occur at the Griffith University Clinical Trial Unit on the Gold Coast.
You are required to have a study partner to attend visits with you.
You will attend MRI and PET scans throughout the trial.
Volunteer to participate
Participation in this study is completely voluntary, and participants can decide to withdraw at any time.
Eligible participants will be reimbursed for their travel associated with each study visit.
Contact Jessica Todd
To learn more about this clinical trial, please contact:
Jessica Todd, Clinical Trial Coordinator.
0401 119 059 clinicaltrialunit@griffith.edu.au
Ethics approval number for the Early AD Trial: Bellberry Limited 2024-02-177, GU HREC 2024/471
Can't see a trial for you?
Join our volunteer database to be contacted about new clinical trials